A PHASE I, SINGLE-CENTER, MIXED METHODS STUDY ON THE HEALTH OUTCOMES OF VISUAL SELF EXPRESSION

A Healthcare Professional, a Patient or Caregiver in the Radiation Oncology Department at the University of Pennsylvania Clinical Trial

Official title:

A PHASE I, SINGLE-CENTER, MIXED METHODS STUDY ON THE HEALTH OUTCOMES OF VISUAL SELF EXPRESSION

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03155672
• Other study ID #: UPCC 01017
• Status: Completed
• Start date: May 15, 2017
• Est. completion date: December 31, 2019

Study information

• Verified date: April 2020
• Source: Abramson Cancer Center of the University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To gain understanding about the impact of visual art making on biomarkers, such as cortisol, alpha amylase, oxytocin, etc. to examine whether and to what extent there are changes in levels of stress and immune function in patients and caregivers adults (including family caregivers and medical professionals)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: December 31, 2019
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Adults between the age of 18 - 70

• A healthcare professional, a patient or caregiver in the Radiation Oncology Department at the University of Pennsylvania

• Subjects must be capable of giving informed consent

Exclusion Criteria:

• Any healthcare professional or patient/caregiver not working in or being seen at Radiation Oncology Department at the University of Pennsylvania

Related Conditions & MeSH terms

• A Healthcare Professional, a Patient or Caregiver in the Radiation Oncology Department at the University of Pennsylvania
• Neoplasms

Intervention

Behavioral:
• Art therapy
Art Therapy

Locations

Country	Name	City	State
United States	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Abramson Cancer Center of the University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	NUmber of changes in levels of stress and immune function in patients and caregivers		1 year